晚期卵巢癌初始治疗阶段新辅助化疗后间隔减瘤术与初次减瘤术的成本效果比较
该研究从美国 Medicare 视角构建 7 个月时间跨度的 Markov 模型,比较晚期上皮性卵巢癌患者接受 3 周期卡铂+紫杉醇新辅助化疗后间隔减瘤术再 3 周期化疗,与初次减瘤术后 6 周期化疗的成本效果。结果显示新辅助化疗组每例患者节省 7034 美元,QALY 增加 0.035,在基础分析中占优;概率敏感性分析中占优策略概率超过 99%。
要点
- 从美国 Medicare 视角,新辅助化疗较初次减瘤术每例节省 7034 美元,QALY 增加 0.035。
- 基础分析中新辅助化疗占优初次减瘤术,概率敏感性分析中占优概率超过 99%。
- 作者认为短期新辅助化疗是晚期上皮性卵巢癌具有成本效果的替代方案。
核心结论
- 短期内新辅助化疗是晚期上皮性卵巢癌具有成本效果的替代方案。
- 这些结果可能转化为长期成本效果,但随机对照试验数据仍在成熟中。
研究设计与样本
- 成本效果分析,采用 Markov 模型,时间跨度为 7 个月,从美国 Medicare 视角开展。
- 比较 3 周期卡铂+紫杉醇新辅助化疗后间隔减瘤术再 3 周期化疗,与初次减瘤术后 6 周期化疗。
- 输入参数包括化疗并发症概率、手术并发症概率、治疗完成率、治疗成本和效用值。
- 模型产出包括成本、获得生命年、获得质量调整生命年(QALY)和增量成本效果比(ICER)。
- 通过蒙特卡洛模拟进行概率敏感性分析。
主要发现
- 新辅助化疗组每例患者节省 7034 美元,QALY 增加 0.035,基础分析中新辅助化疗占优。
- 概率敏感性分析中,新辅助化疗作为占优策略的概率超过 99%。
局限性
- 作者指出随机对照试验数据仍在成熟中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Advanced stage epithelial ovarian cancer (AEOC) can be treated with either neoadjuvant chemotherapy (NACT) or primary cytoreductive surgery (PCS). Although randomized controlled trials show that NACT is non-inferior in overall survival compared to PCS, there may be improvement in short-term morbidity. We sought to investigate the cost-effectiveness of NACT relative to PCS for AEOC from the US Medicare perspective. METHODS: A cost-effectiveness analysis using a Markov model with a 7-month time horizon comparing (1) 3cycles of NACT with carboplatin and paclitaxel (CT), followed by interval cytoreductive surgery, then 3 additional cycles of CT, or (2) PCS followed by 6cycles of CT. Input parameters included probability of chemotherapy complications, surgical complications, treatment completion, treatment costs, and utilities. Model outcomes included costs, life-years gained, quality-adjusted life-years (QALYs) gained, and incremental cost-effectiveness ratios (ICER), in terms of cost per life-year gained and cost per QALY gained. We accounted for differences in surgical complexity by incorporating the cost of additional procedures and the probability of undergoing those procedures. Probabilistic sensitivity analysis (PSA) was performed via Monte Carlo simulations. RESULTS: NACT resulted in a savings of $7034 per patient with a 0.035 QALY increase compared to PCS; therefore, NACT dominated PCS in the base case analysis. With PSA, NACT was the dominant strategy more than 99% of the time. CONCLUSIONS: In the short-term, NACT is a cost-effective alternative compared to PCS in women with AEOC. These results may translate to longer term cost-effectiveness; however, data from randomized control trials continues to mature.
引用
- Tran AQ, Erim DO, Sullivan SA, et al. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase. Gynecol Oncol. 2017. PMID: 29273308. doi:10.1016/j.ygyno.2017.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。